Table 1.
Percentage of VH-VL hallucinated designs with improved FR scores (over wildtype) for a selected set of 9 humanized therapeutic antibodies.
| PDB ID | mAb Name | % Designs with improved total FR Scores |
|---|---|---|
| 1CE1 (38) | Alemtuzumab | 21 |
| 6BFT (39) | Bevacizumab | 74 |
| 6NOV (40) | Ixekizumab | 24 |
| 4LLU (41) | Pertuzumab | 85 |
| 5WUV (42) | Certolizumab | 100 |
| 5B8C (43) | Pembrolizumab | 34 |
| 6TCS (44) | Omalizumab | 36 |
| 5XXY (45) | Atezolizumab | 93 |
| 1N8Z (36) | Trastuzumab | 43 |
A total of 60 designs were obtained for each case with no seeding. See SI Figure 13 for distribution of FR scores per target.